drugset / Trial / NCT00730691
Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-02
- Completion
- 2009-02
Outcome
Missed primary endpoint
paper Differences from placebo in the primary efficacy end-point were not statistically significant for the vortioxetine groups. PMID 24341301 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Duloxetine | Small molecule | 60 mg | Oral |
| Subject | Vortioxetine | Unknown | 2.5 mg | Oral |
| Subject | Vortioxetine | Unknown | 5 mg | Oral |
| Subject | Vortioxetine | Unknown | 10 mg | Oral |